OBX Stock Forecast: Obsidian Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Obsidian Therapeutics, Inc. is $42. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 36 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Obsidian Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (80): The shares have been drifting up relative to others.
Accruals (5): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
OBX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OBX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Sept 2026 | Leerink Partners | Initiates | Outperform | $32 |
| 9 Sept 2026 | William Blair | Initiates | Outperform | — |
| 18 Aug 2026 | LifeSci Capital | Initiates | Outperform | — |
| 5 Aug 2026 | Piper Sandler | Initiates | Overweight | $42 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OBX.
This page is one stock. Monday covers all of them.
OBX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
OBX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
OBX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −113.6%
- Dividend yield
- —
Higher than 2% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Obsidian Therapeutics, Inc. has a market value of $741.3M and an enterprise value of $530.4M.
Obsidian Therapeutics, Inc. employs 87 people.
Data provided by Twelve Data
OBX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at OBX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Obsidian Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about OBX
What is the OBX stock price forecast for 2026-2027?
The median 12-month analyst price target for Obsidian Therapeutics, Inc. is $42, with estimates ranging from $32 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OBX stock a buy right now?
Of the 5 analysts covering Obsidian Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Obsidian Therapeutics, Inc. 36 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OBX?
As at 21 Nov 2026, Obsidian Therapeutics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (80 of 100).
Will OBX stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $42, and Ticker Nerd's factor model ranks Obsidian Therapeutics, Inc. 36 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OBX stock forecast for 2030?
No analyst covering Obsidian Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OBX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $42 over the next 12 months.
What does Obsidian Therapeutics, Inc. do?
Obsidian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on engineered cell and gene therapies for cancer, with an emphasis on solid tumors. The company develops tumor-infiltrating lymphocyte (TIL) therapies built on its proprietary cytoDRiVE platform, which is designed to control protein function using FDA-approved small-molecule drugs.
About Obsidian Therapeutics, Inc.
Obsidian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on engineered cell and gene therapies for cancer, with an emphasis on solid tumors. The company develops tumor-infiltrating lymphocyte (TIL) therapies built on its proprietary cytoDRiVE platform, which is designed to control protein function using FDA-approved small-molecule drugs. Its lead program, OBX-115, is an investigational autologous TIL therapy incorporating membrane-bound IL15 to support T-cell activity, persistence, and antitumor response. Obsidian Therapeutics’ current pipeline centers on next-generation immuno-oncology treatments for advanced melanoma, non-small cell lung cancer, and other solid tumor indications. The company operates within the biotechnology sector, where its platform-based approach combines cell engineering, protein regulation, and clinical development to address difficult-to-treat cancers.
CEO Dr. Madan Jagasia M.D., M.S. · 87 employees · United States · https://obsidiantx.com